| Document |
Document Title |
|
WO1999000399A9 |
C-nucleosides are synthesized by a method in which a sugar is derivatized in a single step to provide a heterocycle at the C1 position, and then the heterocycle is aromatized in another single step. In one class of preferred embodiments ...
|
|
WO/1999/005158A1 |
The present invention relates to a novel and improved process for preparing 2'-fluoro-5-methyl-$g(b)-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepa...
|
|
WO/1999/005157A1 |
The present invention relates to a novel and improved process for preparing 2'-fluoro-5-methyl-$g(b)-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepa...
|
|
WO/1998/030572A1 |
Disclosed are novel synthetic processes for the preparation of the trisaccharide $g(a)Gal(1$m(7)4)$g(b)Gal(1$m(7)4)Glc-OR compounds.
|
|
WO/1998/015270A1 |
The present invention describes a method for treating neuropathic pain comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of formula (I), wherei...
|
|
WO/1998/015544A1 |
A compound and method for producing an enantiomerically enriched epoxide from an olefin using a chiral ketone and an oxidizing agent is disclosed.
|
|
WO/1998/007653A1 |
Novel chiral boron and aluminum hydride complexes, compositions comprising the chiral hydride complexes, and methods for their synthesis and use are described. The novel chiral hydride complexes are of the formulas: MBH�4-n-a?(R*)�n?...
|
|
WO/1998/000129A2 |
Anticonvulsant derivatives useful in treating psoriasis are disclosed.
|
|
WO/1998/000131A1 |
Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) are disclosed.
|
|
WO/1998/000130A2 |
Anticonvulsant derivatives useful in treating obesity are disclosed.
|
|
WO/1997/043295A1 |
D-Pentofuranose derivatives represented by general formulae (1) to (4) and a process for the preparation of compounds of general formula (2) by oxidizing compounds of general formula (1) with a hypochlorite in the presence of a catalytic...
|
|
WO/1997/027205A1 |
This invention pertains to nucleoside analogs which have antiviral activity and improved metabolic stability, compositions comprising them, and methods of antiviral treatment employing them. More particularly, this invention pertains to ...
|
|
WO/1997/027204A1 |
This invention pertains to nucleoside analogs which have antiviral activity and improved metabolic stability. More specifically, this invention pertains to modified sugar benzimidazole nucleosides, as exemplified by compounds such as ben...
|
|
WO/1997/023494A1 |
Methods and compositions are provided which increase the cellular uptake of bioactive materials by covalently bonding such compounds to carbohydrate moieties through chemical linkers using other than glycosidic bonds. Numerous carbohydra...
|
|
WO/1997/019950A1 |
The present invention provides a topiramate immunoassay and reagents for use in the immunoassay. In particular, topiramate is derivatized at the sulfamate moiety or the 9-carbon or 10-carbon methyl group of topiramate to add a label boun...
|
|
WO/1997/018223A1 |
The present invention relates to compositions and methods for inhibiting the aging of amino-containing amino acid, peptides, proteins and biomolecules. Accordingly, a composition is disclosed which comprises an agent or compound capable ...
|
|
WO/1997/017071A1 |
The present invention is directed to a synthetic route for preparing endothelium receptor antagonists of formulae (7B) and (7A) and to the chiral intermediates.
|
|
WO/1997/014710A1 |
Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate linkages are disclosed.
|
|
WO/1997/002034A1 |
The invention pertains to medicine and biologically active substances. The objective is to produce a drug with enhanced therapeutic effects and a broad spectrum of therapeutic properties and suitable for use in the production of highly s...
|
|
WO/1997/001343A2 |
The present invention relates to a new utilization of a sophorolipidic compound, pharmaceutically acceptable salts of the acid form of the sophorolipid and of the ester of the deacetelated sophorolipid acid form as therapeutically active...
|
|
WO/1996/039444A1 |
Inulins are pyrolyzed to di-D-fructose dianhydrides in good yield by heating at atmospheric pressure to a temperature sufficiently high to melt the inulin, or pyrolyzing in the presence of a hydroxy carboxylic acid such as citric acid, t...
|
|
WO/1996/031515A1 |
Esters of hydroxyl-containing indolocarbazoles and acids containing selected solubilizing groups are provided. Compositions including the indolocarbazole esters and methods for the use of the indolocarbazole esters are also provided.
|
|
WO/1996/008503A1 |
A compound of formula (I) or salts thereof, where Ro is hydrogen or together with R7O denotes a C1-C15 hydrocarbylidenedioxy group, R1 is hydrogen, R1a or a group of formula (II), R1a is R1b or a protecting group Q, R1b is C1-C20 alkyl, ...
|
|
WO/1996/005900A1 |
The proposed vacuum distillation process involves dividing the liquid product fed into a vessel under a vacuum into a steam/gas phase and at least one liquid fraction, removal of the steam/gas phase from the vessel using a vacuum-produci...
|
|
WO/1995/035102A1 |
2'-modified pyrimidines are prepared by a novel intramolecular nucleophilic substitution reaction.
|
|
WO/1995/032976A1 |
Staurosporin derivatives of formula (I), wherein R1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical, R2 is an aliphatic, carbocyclic, carbocycli...
|
|
WO/1995/032974A1 |
The utility of known and novel staurosporin derivatives of formula (I), wherein R1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical; R2 is hydrog...
|
|
WO/1995/032975A1 |
Staurosporin derivatives of formula (I), wherein R1 is an acyl radical having from 2 to 30 carbon atoms, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is substituted by acyclic substituents, a cycloaliphatic or cyclo...
|
|
WO/1995/029927A2 |
Glycoconjugate antigens are prepared by preparing a hapten glycoside, especially an alpha glycoside prepared by the Fischer method, with an olefinic aglycon moiety, especially one having a non-terminal double bond, ozonolyzing the hapten...
|
|
WO/1995/015969A1 |
The present invention consists in methods of preparing sugar derivatives either in isolation or from glycopeptides or glycoproteins. The methods comprise producing sugar hydrazones, sugar pyrazoles, glycosylpyrazones, azoglycan dyes and ...
|
|
WO/1995/007700A1 |
A method for protecting against mutational damage in mammalian cells induced by irradiation comprising administering a phosphorothioate or phosphorothioate metabolite to the mammal before or up to 3 hours after irradiation.
|
|
WO/1994/021654A1 |
A process is disclosed for preparing sugar acetals by reacting sugars with ketones in the presence of an acid catalyst. By using an oxonium tetrafluoroborate as acid catalyst, yield and reaction times can be surprisingly improved.
|
|
WO/1994/014827A1 |
Sulfamate derivatives having formula (I), wherein R1, R2, R3, R4, R5 and R6 are as herein defined, have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, the prese...
|
|
WO/1994/013685A1 |
D-psicofuranose and D-psicopyranose derivatives represented by general formulae (I) and (II), useful as the key intermediates in a novel process for producing hydantocidin; wherein R1 through R8 may be the same or different from one anot...
|
|
WO/1994/011381A1 |
Compounds of this invention are derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediates for the synthesis of these compounds. Methods of preparation, pharmaceutical ...
|
|
WO/1994/006799A1 |
A thrombocytopenia remedy containing an indolocarbazole derivative represented by general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient, and a novel indolocarbazole derivative.
|
|
WO/1994/004541A2 |
This invention describes both known and novel compounds, some of which are protein kinase inhibitors, that may be combined with taxol type compounds. The combination of disclosed compounds plus taxol type compounds exhibits powerful syne...
|
|
WO/1993/018040A1 |
Compounds are described of formula (I), wherein R1 represents a hydroxyl group or a group selected from -OCOCH=ECHCH(CH3)(CH2)3CH3, -OCOCH=ECHC(CH3)=ECHCH(CH3)CH2CH3 or -OCO-X-CH2CH(CH3)CH2CH3 [where X is -CH=ECHCH(CH3)-, -CH2CH(OH)CH(CH...
|
|
WO/1993/017689A1 |
A method and pharmaceutical for protecting against genotoxic damage in irradiated cells. Reduction of mutations at the hypoxanthine-guanine phosphoribosyl transferase locus is accomplished by administering an effective dose of a compound...
|
|
WO/1993/018039A1 |
Compounds are described of formula (I), wherein R1 represents a hydroxyl group or a group selected from -OCOCH=ECHCH(CH3)(CH2)3CH3, -OCOCH=ECHC(CH3)=ECHCH(CH3)CH2CH3 or -OCO-X-CH2CH(CH3)CH2CH3[where X is -CH=ECHCH(CH3)-, -CH2CH(OH)CH(CH3...
|
|
WO/1993/007904A1 |
Pharmaceutically acceptable compositions of matter comprising a lipophilic oligosaccharide antibiotic, e.g., the everninomicin-type antibiotic of formula (III), at least a stoichiometric amount of a base, e.g., NMG, an amount of, e.g., h...
|
|
WO/1993/006112A1 |
The present invention relates to an antiviral phosphonate derivate of an acyclic purine nucleoside analog, to pharmaceutically acceptable derivatives thereof and to their use in medical therapy, particularly in the treatment of cytomegal...
|
|
WO/1992/016530A1 |
Compounds are described of formula (I) wherein R1 represents a hydrogen atom or an acetyl group; R2, R3 and R4 may each independently represent a hydrogen atom or a methyl group; n represents an integer from 1 to 3; and the fluorine atom...
|
|
WO/1992/014745A1 |
A solvent-free method for synthesizing an ethereally-substituted, blocked monosaccharide comprising the steps of: 1) mixing, in the absence of solvent, a partially blocked monosaccharide unblocked at one position, an alkyl halide or a su...
|
|
WO/1992/012160A1 |
These compounds inhibit the enzyme squalene synthase and/or are intermediates for the preparation of compounds which inhibit the enzyme squalene synthase. Compounds of the invention may be formulated for use in a variety of conditions wh...
|
|
WO/1992/009276A1 |
The use of compounds of formula (I) for the treatment of cells having an abnormally elevated cell proliferation, which results in diseases such as psoriasis, inflammatory diseases, rheumatic diseases and allergic dermatologic reactions.
|
|
WO/1992/005152A2 |
A process for converting 1,4- and 1,5-dicarbonyl sugars to pyrrolidine and piperidine amino sugars. Novel compounds resulting from this process are also described.
|
|
WO/1992/004359A2 |
Derivatives of simple monosaccharides which exhibit anti-proliferative and/or anti-inflammatory activity and are useful for treating mammals having inflammatory disorders and/or autoimmune disorders. This invention also encompasses pharm...
|
|
WO/1992/002525A1 |
A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. T...
|
|
WO/1991/019728A1 |
A nucleotide derivative represented by general formula (I), which has an excellent pharmacological action and is obtained from a structural derivative other than naturally occurring normal cyclic nucleotides: wherein R1 represents hydrog...
|
